|To: TokyoMex who wrote ()||2/10/2000 10:42:00 PM|
Football Network To Attend Toyota/Dan Marino Celebrity Golf Invitational |
FORT LAUDERDALE, Fla.--(BW SportsWire)--Feb. 9, 2000--TFN, The Football Network, Inc., (OTC BB: TFNK), has announced that it will attend the ninth annual Dan Marino golf tournament sponsored by Toyota.
The event, which has raised millions of dollars for various youth charities chosen by the Dan Marino Foundation, distributes the proceeds throughout the South Florida area.
The four-day event held at the Weston Hills Country Club in Ft. Lauderdale, Florida will begin on February 17th with a pairing party and silent auction. TFN has donated two network letterman jackets to the auction, which will be autographed by Dan Marino and other NFL quarterback icons. TFN President Jantonio Turner will attend the celebrity/amateur event held on the 18th of February. Billy Joel, Marcus Allen, Doug Flutie, Jason Sehorn, D.B. Sweeney, Ivan Lendl, Hootie and the Blowfish, WWF Wrestling star Sgt. Slaughter, Pete Rose, LL Cool J, Dan Quayle, Meatloaf, and Lesley Visser are also among the 130 celebrities slated to attend. The celebrity tournament closes out on February 20th with an awards ceremony.
The Football Network is an integrated multimedia company superserving football enthusiasts by connecting them to the sport via any and all means, including at present the Web and radio and in the future via cable/satellite TV and broadband. For more information, please visit our Website - footballnetwork.com or call us directly at 888-404-TDTV.
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such forward-looking statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
The Football Network, Los Angeles
Tawny White, 323/898-8388; E-MAIL, TawnywithTFN@aol.com
|RecommendKeepReplyMark as Last ReadRead Replies (2)|
|To: TokyoMex who wrote ()||2/13/2000 6:20:00 AM|
ACIT has doubled in a month|
and has lots more to go. Co. went public a few yrs. ago at $6 and fell to .25. Last 3 quarters have been profitable and next one will be too. Stock has been moving up to a little over $1.50 in the last month and I think this one will be back to $6 in the next 9 - 12 months. Low risk, high reward play. Buyers have been accumulating anticipating the break.
|RecommendKeepReplyMark as Last Read|
|To: TokyoMex who wrote ()||2/14/2000 9:58:00 AM|
RGEN - FDA approval today - One of a kind drug.|
Monday February 14, 6:45 am Eastern Time
Company Press Release
SOURCE: Repligen Corporation
Repligen Issued Broad U.S. Patent For Use of Secretin In The Treatment of Autism
NEEDHAM, Mass., Feb. 14 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN - news) today announced it was awarded a U.S. patent for the use of secretin in the treatment of autism spectrum disorder and its symptoms. U.S. patent No. 6,020,310 is entitled ``Method for assisting in differential diagnosis and treatment of autistic syndromes.'
The patent, which will remain in force until 2018, covers intravenous administration of secretin for the treatment of autism spectrum disorder and its symptoms, as well as methods where secretin is co-administered with a permeation-enhancing agent.
In March 1999, Repligen acquired exclusive rights to a series of patent applications for the use of secretin, a naturally-occurring hormone currently approved to diagnose certain gastrointestinal conditions, as a potential autism therapy. Some autistic children who have received the hormone therapeutically have made improvements in social behavior, communication, gastrointestinal function and sleep. Repligen is developing a human synthetic form of secretin for evaluation in clinical trials in pediatric autism.
``This patent allowance gives us a strong proprietary position with regard to secretin as a potential new treatment for autism, a pervasive and debilitating developmental disorder for which there are no FDA approved treatments currently available,' said Walter C. Herlihy, Ph.D., President and CEO of Repligen. ``We are currently prosecuting additional patent applications in the United States and Europe to further strengthen our position.'
The patent also discloses a previously unrecognized relationship between the response of the pancreas to secretin stimulation and autism. A recent study published in the Journal of Pediatrics (Horvath et al, Journal of Pediatrics 135 (5): 559-63) showed that 75% of autistic children with gastrointestinal symptoms had a significantly greater pancreatic response to secretin compared to children without the disorder, suggesting lack of normal secretin stimulation in this subset of autistic patients. Conducted at the University of Maryland Medical Center, the study was designed to understand the underlying biology of secretin in autism.
Autism is a neurological disorder that typically appears during the first three years of life and is characterized by defects in social interaction, communication and abnormal behavior. It is the third most common developmental disability in the United States today, affecting at least half-a-million people. There is no FDA-approved treatment for autism.
Repligen Corporation develops new drugs for autism, organ transplant and cancer. Repligen also manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to produce therapeutic antibodies. Its corporate headquarters are located at 117 Fourth Avenue, Needham MA, 02494. Additional information may be requested from www.repligen.com.
|RecommendKeepReplyMark as Last ReadRead Replies (1)|